Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypoxisome
- Development stage
- Preclinical
- Lead developer
- Exostemtech
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
Hypoxisome is an exosome-based therapeutic candidate developed by Exostemtech, specifically targeting lung fibrosis and idiopathic pulmonary fibrosis (IPF). The therapy consists of exosomes derived from mesenchymal stem cells (MSCs) that have been cultured under hypoxic conditions, a process that enhances the secretion of anti-fibrotic and anti-inflammatory factors. Hypoxisome works by modulating the lung microenvironment and inhibiting the TGF-beta signaling pathway, which is a key driver of fibroblast-to-myofibroblast differentiation and excessive extracellular matrix production. By delivering a specialized cargo of microRNAs and proteins, it aims to halt or reverse the progression of fibrotic lung disease. It is currently in preclinical development.
- Brand names
- Hypoxisome
- Other names
- Hypoxia-preconditioned mesenchymal stem cell-derived exosomesHypoxia-induced exosomes
02
Targets
SMAD3 (SMAD family member 3)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on Hypoxisome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hypoxisome.